|
Tuesday, March 31, 2015. A randomized trial reported in the November-December 2014 issue of the Journal of Clinical Lipidology found lower inflammation, triglycerides and low-density lipoprotein (LDL) cholesterol in men and women given the omega-7 fatty acid palmitoleic acid in comparison with a placebo. "Our objective was to conduct the first randomized controlled trial of purified palmitoleic acid supplementation in humans," write authors Adam M. Bernstein, MD, ScD, and Michael F. Roizen, MD, of the Cleveland Clinic, along with Luis Martinez, MD, MPH, of Xyrion Medical Institute. "We hypothesized that supplementation would improve serum lipids and decrease inflammation."
The trial included 60 adults between the ages of 17 and 70 years who had lipid abnormalities as well as mild systemic inflammation as evidenced by elevated C-reactive protein (CRP) levels. Participants were randomized to receive a capsule containing 220.5 milligrams cis-palmitoleic acid or a placebo for 30 days. Blood samples collected before and after the treatment period were analyzed for high-density lipoprotein (HDL) and LDL cholesterol, triglycerides, CRP and other factors.
Among subjects who received palmitoleic acid, HDL cholesterol increased by 5%, and LDL cholesterol, triglycerides and CRP decreased by 8%, 15% and 44% in comparison with the control group.
"These findings build on a growing body of in vitro, animal, and human studies, demonstrating the importance of palmitoleic acid to regulating metabolism," the authors conclude. "Thus, purified palmitoleic acid may be a therapeutic approach in helping maintain lipid levels within a healthy range as well as improving inflammatory markers in patients with mild dyslipidemia and inflammation."
|
|